Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

Impact · against what's priced in

Vanda Pharmaceuticals receives a strong positive catalyst from clinical success in reducing Wegovy-induced vomiting, opening a pathway toward the high-growth GLP-1 market. Novo Nordisk may see long-term benefits from improved patient adherence, though the impact is marginal relative to its current scale.

VNDA+0.60: No priced-in read yet

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

What matters in this story

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

What matters in this story

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

How each ticker is affected

Connected tickers

Track these names every morning.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Roche Expands Obesity Pipeline With Rona's RNAi Candidate

BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

What matters in this story

Next reads from the same story arc

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients

What matters in this story

Next reads from the same story arc

Biomea Fusion, Inc. (BMEA) Discusses BMF-650 Phase I Topline Results and Potential for Separating GI Side Effects from Weight Loss Transcript

How each ticker is affected

Connected tickers

Track these names every morning.

Vanda says anxiety drug failed main goal of late-stage study, puts program on hold

Roche Expands Obesity Pipeline With Rona's RNAi Candidate

BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meeting

DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform